Lexicon Pharma (LXRX) Tops Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.29 -0.43%
EPS Growth %: -600.0%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
ORPB, ONEG, NDLS, More
EPS Growth %: -600.0%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
ORPB, ONEG, NDLS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.34), $0.02 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $566 thousand versus the consensus estimate of $370 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Noodles & Company (NDLS) Tops Q2 EPS by 26c ; Offers Guidance
- TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
